Merck river blindness case study

Essay on Merck and Co. River Blindness - 1531 Words. For centuries, river blindness (onchocerciasis) plagued remote communities in Africa, Latin America and Yemen, and there was no answer to this affliction. Presentation due in Week Five by reading one of the following case studies from Managing Business Ethics as assigned by your facilitator. The case studies are found in the text near the end of the given chapter. o Merck and River Blindness in Ch. 2 o Pinto Fires in Ch. 4 o Sears, Roebuck, and Co.

Essay on Merck and Co. River Blindness - 1531 This all began to change in the mid-to-late 1970s, when Dr. Mohammed Aziz, championed the clinical development of Mectizan. Aziz led the collaboration with the World Health Organization (WHO) in the early 1980s to design and implement field studies in West Africa that, ultimately, proved the effectiveness of the drug against river blindness. Merck - River Blindness 1652 Words 7 Pages. Merck and Co. and river blindness MANUEL VELASQUEZ, Business Ethics. Concepts and cases 4th edt. Prentice Hall, Upper Saddle River, New Jersey, 1998 River blindness is an agonizing disease that affects some 18 million impoverished people living in remote villages along the banks of rivers in tropical regions of Africa

Merck Offers Free Distribution of New River Blindness Drug. William Campbell of Merck Research Laboratories suggested the use of ivermectin (later named Mectizan) for river blindness in humans. In 1987, Merck committed to donate Mectizan - as much as needed, for as long as needed - with the goal to help eliminate river blindness. River blindness, or onchocerciasis, afflicts 18 million people in West and Central Africa, the Middle East and Central and South America, according to Dr. P. Roy Vagelos, the chairman of Merck.

Merck Case - In order to reach this goal, Merck leaders recognized that many organizations with unique skills would need to work together as a team. Merck had built a research team dedicated to alleviating human suffering. What would a refusal to pursue a possible treatment for river blindness do to morale? Ultimately, it was Dr. Vagelos who had to make the decision whether or not to fund research toward a treatment for river blindness.

Add review

Your e-mail will not be published. Required fields are marked *